Neurology Emergency Medicine Strong — NICE CG137 / Berg 1991
First Unprovoked Seizure — Recurrence Risk
Recurrence risk after a first unprovoked seizure: the risk factors from the AAN/AES guideline (information page — there is no validated points score).
Used in: Seizures & Epilepsy
References
- Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults (AAN/AES). Neurology. 2015;84(16):1705–1713.
- Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. 1991;41(7):965–972.
- NICE NG217. Epilepsies in children, young people and adults. 2022.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Promethazine hydrochloride · First-generation H1-antihistamine (phenothiazine)
- Tolbutamide · First-generation sulfonylurea (short-acting)
- Chlorphenamine (Chlorpheniramine) · Sedating Antihistamine (H1 Antagonist — First-generation)
- Cyproheptadine hydrochloride · First-generation antihistamine + 5-HT₂A antagonist
- Sodium Valproate (Epilepsy in Elderly) · Antiepileptic
- Cefalexin · First-Generation Cephalosporin — Skin / Soft Tissue / UTI
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.